Early screening, first-line therapy choice critical
Cleveland Clinic-led study lays groundwork for more personalized treatments
Luspatercept shows promise for patients with few options
Searching for new insights into drug resistance, collateral sensitivity
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
These research results will have impact in 2020
CHIP Clinic's goals: Research, preventive care
Study suggests limited role for CET in this cancer type
Study assesses outcomes of therapies with novel agents
Autologous anti-CD19 agent produces impressive survival improvements
Interim results of phase 2 trial are promising
Advertisement
Advertisement